Organogenesis Holdings Inc

Insider buying spurs optimism for Organogenesis Holdings (ONSG). CEO Grow Brian’s 958‑share purchase signals confidence and potential upside amid biotech market volatility.

Leibowitz Arthur S buys 5,000 Organogenesis shares at $2.68, reflecting steady insider confidence despite a 30% recent dip—ideal for investors tracking biotech growth.

Board‑member buy at $2.67 signals confidence in Organogenesis Holdings as revenue rises, hinting at potential upside despite recent decline.

Freedman Lori’s February 2026 trades at Organogenesis reveal a blend of RSU grants, share purchases, and modest sales, signaling long‑term confidence while maintaining liquidity for investors.

Insider selling spikes at Organogenesis Holdings – CFO and top execs sell 400k+ shares, hinting at doubts over future prospects and potential price correction.